Review
Oncology
Amber B. Jones, Abbey Rocco, Lawrence S. Lamb, Gregory K. Friedman, Anita B. Hjelmeland
Summary: Immune surveillance during cellular stress is crucial for maintaining homeostasis. Understanding the regulatory mechanisms controlling NKG2D ligands in cancer is important for targeted therapeutic approaches and enhancing the field of NKG2D ligand biology.
Article
Biology
Payal Dhar, Fahmin Basher, Zhe Ji, Lei Huang, Si Qin, Derek A. Wainwright, Jerid Robinson, Shaye Hagler, Jing Zhou, Sean MacKay, Jennifer D. Wu
Summary: Research shows that tumor-derived NKG2D ligand soluble MIC can reprogram NK cells and provides a rationale for targeting sMIC to enhance the efficacy of current NK cell-based cancer immunotherapies.
COMMUNICATIONS BIOLOGY
(2021)
Article
Immunology
Cassiano Martin Batista, Leonardo Foti
Summary: COVID-19, caused by SARS-CoV-2, has been declared as a pandemic since March 2020. Key measures to prevent transmission include physical distancing, mask-wearing, and hand hygiene. Vaccines are crucial in reducing the impact of the pandemic, but face challenges in production and distribution. Research has highlighted the interaction between the virus protein and the ACE2 receptor, leading to the emergence of nAbs as a therapeutic approach.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Yiying Zhu, Zhangxun Zhao, Minggao Xue, Dan Wang, Guifeng Su, Xiaoman Ju, Qihong Yang, Shaohua Zhang, Dongmei Fan, Huifang Zhu, Min Yu, Yan Li, Lingmei Kong, Hongyu Zhou
Summary: Activation of the NKG2D receptor can enhance the sensitivity of leukemia cells to NK cell cytotoxicity, and this can be achieved through the use of drugs such as Ciclopirox Olamine (CPX). CPX can increase the expression of NKG2D ligands (NKG2DLs) on leukemia cells, thereby enhancing the efficacy of NK cell-mediated immunotherapy.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Immunology
Maresa Lopez-Montan, Laura Jimenez-Ortega, Teresa Rocio Cruz-Hernandez, Victor Gabriel Hernandez-Chavez, Laura Arcelia Montiel-Cervantes, Elba Reyes-Maldonado, Jorge Vela-Ojeda
Summary: Non-Hodkin's lymphoma (NHL) is a common hematologic malignancy in humans and dogs. This study investigated the role of NK cells and their receptors and ligands in canine lymphoma. The results showed increased numbers of NK cells in dogs with lymphoma and higher levels of soluble molecules sMIC-A and sMIC-B.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
(2023)
Article
Immunology
Maresa Lopez-Montano, Laura Jimenez-Ortega, Teresa Rocio Cruz-Hernandez, Victor Gabriel Hernandez-Chavez, Laura Arcelia Montiel-Cervantes, Elba Reyes-Maldonado, Jorge Vela-Ojeda
Summary: This study analyzed the role of NK cells, their activating receptors NKG2D and NKp46, and their ligands MIC-A and MIC-B, as well as soluble molecules sMIC-A and sMIC-B in dogs with Non-Hodkin's lymphoma. The study found that dogs with lymphoma had higher numbers of NK cells and increased levels of sMIC-A and sMIC-B.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
(2023)
Article
Biochemical Research Methods
Xiaoming Zhong, Hongqun Liao, Shaowen Hu, Kaiyuan Luo, Huifang Zhu
Summary: The natural product adenanthin significantly promotes the expression of NKG2D ligands in hepatoma cells, improving the killing activity of NK cells against liver cancer cells. This study is the first to report the anti-cancer effects of adenanthin mediated by indirect activation of NK cells. Adenanthin may be used as a sensitizing agent for NK cells in tumor immunotherapy.
MOLECULAR AND CELLULAR PROBES
(2021)
Article
Medical Laboratory Technology
Jian-Hang Xue, Yong-Jing Wang, Wei Li, Qiu-Ling Li, Qiu-Yan Xu, Jian-Jun Niu, Li-Li Liu
Summary: There is a strong correlation between neutralizing antibodies and anti-receptor-binding domain (RBD) IgG antibodies, suggesting that anti-RBD IgG antibody levels can accurately assess immunity following SARS-CoV-2 infection or vaccination.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2022)
Article
Medicine, Research & Experimental
Guojuan Miao, Xiuhong Sun
Summary: An immunomodulatory antibody targeting B7-H4 was successfully generated, showing inhibitory activity on T cell immune suppression and ADCC activity in B7-H4-positive tumors. This antibody could potentially serve as a promising immunotherapy for B7-H4-expressing tumors.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Immunology
Baolin Liao, Zhao Chen, Peiyan Zheng, Linghua Li, Jianfen Zhuo, Fang Li, Suxiang Li, Dingbin Chen, Chunyan Wen, Weiping Cai, Shanhui Wu, Yanhong Tang, Linwei Duan, Peilan Wei, Fangli Chen, Jinwei Yuan, Jinghong Yang, Jiaxin Feng, Jingxian Zhao, Jincun Zhao, Baoqing Sun, Airu Zhu, Yimin Li, Xiaoping Tang
Summary: Characterizing the serologic features of asymptomatic SARS-CoV-2 infection is crucial for diagnostics and control. This study found that asymptomatic infections exhibit weaker overall antibody responses, primarily inducing IgG antibody responses. Anti-S2-IgG shows better sensitivity in identifying asymptomatic infections early after infection compared to anti-RBD-IgG.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Adeline Raynaud, Klervi Desrumeaux, Laurent Vidard, Elise Termine, Daniel Baty, Patrick Chames, Emmanuelle Vigne, Brigitte Kerfelec
Summary: The NKG2D receptor, expressed by cytotoxic immune cells, plays a central role in immune responses against cellular threats. Specific antibodies targeting NKG2D can modulate immune responses and show both activating and inhibitory effects. Bispecific antibodies targeting NKG2D and other molecules such as HER2 on tumor cells can induce cytotoxicity in a tumor-specific manner. These antibodies can retain cytotoxic activity in the presence of ligands, overcoming immunosuppressive effects in the microenvironment.
Letter
Peripheral Vascular Disease
Juan M. Perez Saez, Pablo F. Hockl, Alejando J. Cagnoni, Santiago P. Mendez Huergo, Pablo A. Garcia, Sabrina G. Gatto, Juan P. Cerliani, Diego O. Croci, Gabriel A. Rabinovich
Summary: Galectins, particularly Gal-1, control tumor progression by modulating angiogenesis and immunosuppression, and a newly developed neutralizing anti-human Gal-1 monoclonal antibody (Gal-1-mAb3) shows potential therapeutic benefits by targeting a unique epitope in Gal-1 protein and exerting both angioregulatory and immunomodulatory activities.
Article
Immunology
Mehdi Mohammadi, Mahmood Jeddi-Tehrani, Forough Golsaz-Shirazi, Mohammad Arjmand, Tannaz Bahadori, Mohammad Ali Judaki, Fariba Shiravi, Hengameh Ahmadi Zare, Farzaneh Notash Haghighat, Maryam Mobini, Mohammad Mehdi Amiri, Fazel Shokri
Summary: Overexpression of HER2 is common in many types of cancer, and the novel bispecific anti-HER2 antibody trasintuzumab, which combines trastuzumab and hersintuzumab, shows promising anti-tumor activity in preclinical studies, suggesting its potential as a therapeutic candidate for HER2-overexpressing cancers.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Man Hagiyama, Takahiro Mimae, Akihiro Wada, Fuka Takeuchi, Azusa Yoneshige, Takao Inoue, Naoyuki Kotoku, Hironobu Hamada, Yoshitaka Sekido, Morihito Okada, Akihiko Ito
Summary: Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with limited therapeutic options. This study investigates the potential of anti-CADM1 antibodies as a novel therapeutic approach for MPM. The antibodies showed growth-suppressive effects on CADM1-positive MPM cells and could serve as both antibody drugs and drug vectors.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Immunology
Qiu-Yan Xu, Jian-Hang Xue, Yao Xiao, Zhi-Juan Jia, Meng-Juan Wu, Yan-Yun Liu, Wei-Li Li, Xian-Ming Liang, Tian-Ci Yang
Summary: An urgent need for a highly protective vaccine against COVID-19 exists. This study evaluated the response and duration of 5 subsets of anti-SARS-CoV-2 antibodies post-vaccination, and found intense but decaying antibody response with the CoronaVac vaccine, suggesting the need for booster doses in vaccine strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
